Advertisement

European Radiology

, Volume 26, Issue 12, pp 4649–4655 | Cite as

Adipose tissue and muscle attenuation as novel biomarkers predicting mortality in patients with extremity sarcomas

  • Joyce Veld
  • Josephina A. Vossen
  • Karen De Amorim Bernstein
  • Elkan F. Halpern
  • Martin Torriani
  • Miriam A. BredellaEmail author
Musculoskeletal

Abstract

Objectives

To assess CT-attenuation of abdominal adipose tissue and psoas muscle as predictors of mortality in patients with sarcomas of the extremities.

Methods

Our study was IRB approved and HIPAA compliant. The study group comprised 135 patients with history of extremity sarcoma (mean age: 53 ± 17 years) who underwent whole body PET/CT. Abdominal subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and psoas muscle attenuation (HU) was assessed on non-contrast, attenuation-correction CT. Clinical information including survival, tumour stage, sarcoma type, therapy and pre-existing comorbidities were recorded. Cox proportional hazard models were used to determine longitudinal associations between adipose tissue and muscle attenuation and mortality.

Results

There were 47 deaths over a mean follow-up period of 20 ± 17 months. Higher SAT and lower psoas attenuation were associated with increased mortality (p = 0.03 and p = 0.005, respectively), which remained significant after adjustment for age, BMI, sex, tumor stage, therapy, and comorbidities (p = 0.002 and p = 0.02, respectively). VAT attenuation was not associated with mortality.

Conclusion

Attenuation of SAT and psoas muscle, assessed on non-contrast CT, are predictors of mortality in patients with extremity sarcomas, independent of other established prognostic factors, suggesting that adipose tissue and muscle attenuation could serve as novel biomarkers for mortality in patients with sarcomas.

Key Points

CT-attenuation of adipose tissue and muscle predict mortality in sarcoma patients

CT-attenuation predicts mortality independent of established prognostic factors

Patients with sarcomas often undergo CT for staging or surveillance

Adipose tissue and muscle attenuation could serve as biomarkers for mortality

Keywords

Computed tomography (CT) Adipose tissue attenuation Muscle attenuation Hounsfield Units Sarcoma 

Notes

Acknowledgments

The scientific guarantor of this publication is Miriam A. Bredella. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. Elkan F. Halpern, Director of Statistics of the Department of Radiology at MGH and co-author on the study kindly provided statistical advice for this manuscript. Institutional Review Board approval was obtained. Written informed consent was waived by the Institutional Review Board. Methodology: retrospective, observational, performed at one institution.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

Supplementary material

330_2016_4306_MOESM1_ESM.docx (184 kb)
Supplemental Figure DOCX 184 kb)

References

  1. 1.
    Stiller CA, Trama A, Serraino D et al (2013) Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 49:684–695CrossRefPubMedGoogle Scholar
  2. 2.
    Morrison BA (2003) Soft tissue sarcomas of the extremities. Proc (Baylor Univ Med Cent) 16:285–290Google Scholar
  3. 3.
    Tzeng CW, Smith JK, Heslin MJ (2007) Soft tissue sarcoma: preoperative and postoperative imaging for staging. Surg Oncol Clin N Am 16:389–402CrossRefPubMedGoogle Scholar
  4. 4.
    Dirat B, Bochet L, Dabek M et al (2011) Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 71:2455–2465CrossRefPubMedGoogle Scholar
  5. 5.
    Nieman KM, Romero IL, Van Houten B, Lengyel E (1831) Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013:1533–1541Google Scholar
  6. 6.
    Andarawewa KL, Motrescu ER, Chenard MP et al (2005) Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res 65:10862–10871CrossRefPubMedGoogle Scholar
  7. 7.
    Martinez-Outschoorn UE, Sotgia F, Lisanti MP (2012) Power surge: supporting cells "fuel" cancer cell mitochondria. Cell Metab 15:4–5CrossRefPubMedGoogle Scholar
  8. 8.
    Boutin RD, Yao L, Canter RJ, Lenchik L (2015) Sarcopenia: current concepts and imaging implications. AJR Am J Roentgenol 205:W255–W266CrossRefPubMedGoogle Scholar
  9. 9.
    Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539–1547CrossRefPubMedGoogle Scholar
  10. 10.
    Murphy RA, Register TC, Shively CA et al (2014) Adipose tissue density, a novel biomarker predicting mortality risk in older adults. J Gerontol A Biol Sci Med Sci 69:109–117CrossRefPubMedGoogle Scholar
  11. 11.
    Rosenquist KJ, Massaro JM, Pedley A et al (2015) Fat quality and incident cardiovascular disease, all-cause mortality and cancer mortality. J Clin Endocrinol Metab 100:227–234CrossRefPubMedGoogle Scholar
  12. 12.
    Dahlman I, Mejhert N, Linder K et al (2010) Adipose tissue pathways involved in weight loss of cancer cachexia. Br J Cancer 102:1541–1548CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mracek T, Stephens NA, Gao D et al (2011) Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer 104:441–447CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rolland Y, Abellan van Kan G, Gillette-Guyonnet S, Vellas B (2011) Cachexia versus sarcopenia. Curr Opin Clin Nutr Metab Care 14:15–21CrossRefPubMedGoogle Scholar
  15. 15.
    Di Sebastiano KM, Yang L, Zbuk K et al (2013) Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. Br J Nutr 109:302–312CrossRefPubMedGoogle Scholar
  16. 16.
    Fujiwara N, Nakagawa H, Kudo Y et al (2015) Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 63:131–140CrossRefPubMedGoogle Scholar
  17. 17.
    Miljkovic I, Kuipers AL, Cauley JA et al (2015) Greater skeletal muscle fat infiltration is associated with higher all-cause and cardiovascular mortality in older men. J Gerontol A Biol Sci Med Sci 70:1133–1140CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tamandl D, Paireder M, Asari R et al () Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur RadiolGoogle Scholar
  19. 19.
    Vettor R, Milan G, Franzin C et al (2009) The origin of intermuscular adipose tissue and its pathophysiological implications. Am J Physiol Endocrinol Metab 297:E987–E998CrossRefPubMedGoogle Scholar
  20. 20.
    Zoico E, Rossi A, Di Francesco V et al (2010) Adipose tissue infiltration in skeletal muscle of healthy elderly men: relationships with body composition, insulin resistance, and inflammation at the systemic and tissue level. J Gerontol A Biol Sci Med Sci 65:295–299CrossRefPubMedGoogle Scholar
  21. 21.
    Fujiki H, Sueoka E, Suganuma M (2013) Tumor promoters: from chemicals to inflammatory proteins. J Cancer Res Clin Oncol 139:1603–1614CrossRefPubMedGoogle Scholar
  22. 22.
    Bredella MA, Gill CM, Rosen CJ et al (2014) Positive effects of brown adipose tissue on femoral bone structure. Bone 58:55–58CrossRefPubMedGoogle Scholar
  23. 23.
    Shen W, Punyanitya M, Wang Z et al (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97:2333–2338CrossRefPubMedGoogle Scholar
  24. 24.
    Borkan GA, Gerzof SG, Robbins AH et al (1982) Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 36:172–177PubMedGoogle Scholar
  25. 25.
    Maurovich-Horvat P, Massaro J, Fox CS et al (2007) Comparison of anthropometric, area- and volume-based assessment of abdominal subcutaneous and visceral adipose tissue volumes using multi-detector computed tomography. Int J Obes (Lond) 31:500–506CrossRefGoogle Scholar
  26. 26.
    Bramer JA, van Linge JH, Grimer RJ, Scholten RJ (2009) Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 35:1030–1036CrossRefPubMedGoogle Scholar
  27. 27.
    Kang S, Kim HS, Kim W et al (2015) Comorbidity is independently associated with poor outcome in extremity soft tissue sarcoma. Clin Orthop Surg 7:120–130CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Pakos EE, Nearchou AD, Grimer RJ et al (2009) Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer 45:2367–2375CrossRefPubMedGoogle Scholar
  29. 29.
    Brennan MF, Antonescu CR, Moraco N, Singer S (2014) Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg 260:416–421, discussion 421-412CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Mullen JT, Hornicek FJ, Harmon DC et al (2014) Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer 120:3676–3682CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Choi YY, Kim JY, Yang SO (2014) PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions. Semin Musculoskelet Radiol 18:133–148CrossRefPubMedGoogle Scholar
  32. 32.
    Sheikhbahaei S, Marcus C, Hafezi-Nejad N et al (2015) Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas. PET Clin 10:375–393CrossRefPubMedGoogle Scholar
  33. 33.
    Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2:862–871CrossRefPubMedGoogle Scholar
  34. 34.
    Goodpaster BH, Kelley DE, Thaete FL et al (2000) Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (1985) 89:104–110Google Scholar
  35. 35.
    Yip C, Goh V, Davies A et al (2014) Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol 24:998–1005CrossRefPubMedGoogle Scholar
  36. 36.
    Kelley DE, Goodpaster BH (2001) Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 24:933–941CrossRefPubMedGoogle Scholar
  37. 37.
    Goodpaster BH, Carlson CL, Visser M et al (2001) Attenuation of skeletal muscle and strength in the elderly: the health ABC study. J Appl Physiol (1985) 90:2157–2165Google Scholar
  38. 38.
    Lang T, Cauley JA, Tylavsky F et al (2010) Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. J Bone Miner Res 25:513–519CrossRefPubMedGoogle Scholar
  39. 39.
    Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© European Society of Radiology 2016

Authors and Affiliations

  • Joyce Veld
    • 1
  • Josephina A. Vossen
    • 1
  • Karen De Amorim Bernstein
    • 2
  • Elkan F. Halpern
    • 3
  • Martin Torriani
    • 1
  • Miriam A. Bredella
    • 1
    Email author
  1. 1.Division of Musculoskeletal Imaging and Intervention, Department of RadiologyMassachusetts General Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Department of Radiation Oncology, Francis H Burr Proton Therapy CenterMassachusetts General Hospital and Harvard Medical SchoolBostonUSA
  3. 3.Institute of Technology AssessmentMassachusetts General Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations